Artrya Limited, a medical technology company, engages in the development and commercialisation of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. The company offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography scans which identifies and manages patients at risk of a heart attack. Artrya Limited was incorporated in 2018 and is based in West Perth, Australia.